Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXL770 in male subjects with adrenomyeloneuropathy
NL-OMON51808Phase 2Withdrawn
- Sponsor
- Poxel SA
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of PXL770 in adrenomyeloneuropathy (AMN) and adrenoleukodystrophy (ALD) (2 arms), sponsored by Poxel SA. Primary endpoints: Cmax of PXL770 and AUC of PXL770. Planned start Feb 2022; status: withdrawn.
02
Drugs
PXL770
03
Conditions
adrenomyeloneuropathy (AMN)adrenoleukodystrophy (ALD)
Beyond the preview
Go deeper on NL-OMON51808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51808.